Joanne battles stage 4 kidney cancer
Four years ago, Joanne Romero, who lives in Texas, was diagnosed with stage 4 kidney cancer when she was 26 weeks pregnant. Despite her challenges, Joanne remains positive and hopes her story serves as an inspiration to others.   My journey began on Feb. 16, 2015. I was currently 26 weeks pregnant. I was experiencing a cough that continued to get worse. That day, I was scheduled to have a lung procedure to see what was causing the cough. My high-risk OB ordered an ultrasound the night before. She wanted to make sure my baby was doing well enough for the procedure. During the ultrasound, the ultrasound tech a...
Source: Kidney Cancer Association - March 18, 2019 Category: Urology & Nephrology Source Type: news

Dr. Marc-Oliver Grimm provided an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session
In this article, Dr. Marc-Oliver Grimm provides an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session.03/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 18, 2019 Category: Urology & Nephrology Source Type: news

Extra Weight in Adolescence Tied to Later Risk for Renal Cancer
Among Swedish men, overweight or obesity during adolescence tied to higher risk for renal cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 16, 2019 Category: Cancer & Oncology Tags: Family Medicine, Nephrology, Nursing, Oncology, Pediatrics, Urology, Journal, Source Type: news

Extra Weight in Adolescence Tied to Later Risk for Renal Cancer
FRIDAY, March 15, 2019 -- Overweight and obesity in adolescence is associated with an increased risk for developing renal cell carcinoma (RCC) later in life, according to a study published online Feb. 20 in the International Journal of Cancer. Anna... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 15, 2019 Category: Pharmaceuticals Source Type: news

Antibiotics Before Checkpoint Inhibitors Tied to Worse Survival
Use of broad-spectrum antibiotics 30 days before starting an immune checkpoint inhibitor was associated with a dramatic reduction in cancer patients' survival, a prospective study found.03/11/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 11, 2019 Category: Urology & Nephrology Source Type: news

Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer
The treatment of metastatic clear cell renal cancer is changing rapidly, with the focus switching from vascular endothelial growth factor-targeted therapies to immune checkpoint inhibitors and novel combinations.03/07/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 7, 2019 Category: Urology & Nephrology Source Type: news

Cabozantinib Shows Promise in Non-Clear-Cell Kidney Cancer Cabozantinib Shows Promise in Non-Clear-Cell Kidney Cancer
Cabozantinib demonstrated promising anti-tumor activity in non-clear-cell renal cell carcinoma, a less common type of kidney cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Toxicity, Clinical Outcomes of Varying Cabozantinib Dosage in Metastatic RCC
While clinical outcomes may be comparable in patients with metastatic renal cell carcinoma (RCC) who are treated with full vs reduced dose of cabozantinib, reduced dose may not be associated with decreased adverse events.03/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 6, 2019 Category: Urology & Nephrology Source Type: news

JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCC
Research presented at ASCO GU 2019 compared PFS with avelumab and axitinib vs sunitinib in patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 6, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients
This study investigates its clinicopathologic characteristics and outcomes at a national level.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news

A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma
This study aims to investigate the gene expression changes in papillary renal cell carcinoma(pRCC) and screen several genes and associated pathways of papillary renal cell carcinoma progression.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advanced renal cell carcinoma03/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2019 Category: Urology & Nephrology Source Type: news

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence of kidney cancer.02/27/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 27, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: When to Obtain Genetic Testing for Syndromic Renal Cell Cancer
Dr. Brian Schuch weighs in on genetic testing for kidney cancer.02/26/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 26, 2019 Category: Urology & Nephrology Source Type: news

Top Medications Used to Treat Kidney (Renal Cell Cancer)
This article discusses the top medications used to treat kidney cancer.02/25/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 25, 2019 Category: Urology & Nephrology Source Type: news

Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma
Does the VEGF inhibitor axitinib reduce risk of recurrence in patients with locoregional RCC post nephrectomy?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Company may have leaked carcinogen into air for years
Breathing in high concentrations of the chemical TCE has been linked to kidney cancer, liver cancer and lymphoma (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 22, 2019 Category: Consumer Health News Source Type: news

Being overweight in adolescence may increase kidney cancer risk later in life
(Wiley) Being overweight has been linked with a higher risk of developing a form of kidney cancer called renal cell carcinoma (RCC) among adults, but it's unclear if this risk is present during adolescence. In an International Journal of Cancer study of adolescents who were followed for 37 years, researchers observed a trend for higher RCC risk with increasing body mass index during adolescence, where one-unit increase in body mass index conferred a six percent increased risk of RCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2019 Category: Cancer & Oncology Source Type: news

Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC
First-line treatment with the anti-PD-1 immunotherapy pembrolizumab plus the VEGF-targeted tyrosine-kinase inhibitor axitinib extended overall survival and progression-free survival in patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib, in the phase 3 KEYNOTE-426 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 21, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non –clear cell renal cell carcinoma (RCC).02/20/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2019 Category: Urology & Nephrology Source Type: news

Pembrolizumab Active in Non-Clear Cell Kidney Cancer Pembrolizumab Active in Non-Clear Cell Kidney Cancer
Pembrolizumab monotherapy demonstrated promising antitumor activity when used as a first-line therapy agent in patients with non-clear cell renal carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer
Two large trials show benefits for pembrolizumab - axitinib and avelumab - axitinib versus sunitinib (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 20, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer
WEDNESDAY, Feb. 20, 2019 -- For first-line therapy of metastatic renal cell carcinoma, pembrolizumab plus axitinib and avelumab plus axitinib both show improved survival versus sunitinib, according to two studies published online Feb. 16 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 20, 2019 Category: Pharmaceuticals Source Type: news

' Exciting Times' With Immunotherapy for Kidney Cancer'Exciting Times' With Immunotherapy for Kidney Cancer
New combinations with immunotherapy are going to change the standard of care in metastatic renal cell carcinoma, but questions remain, and there are technicalities to consider, according to some experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 19, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Option in Advanced Non-Clear Cell Kidney Cancer
(MedPage Today) -- Study of single-agent PD-1 inhibitor sets " new bar, says expert (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 19, 2019 Category: Hematology Source Type: news

New therapeutic target found for aggressive pediatric cancers with few treatment options
Researchers at the University of Texas MD Anderson Cancer Center recently discovered a new therapeutic target for malignant rhabdoid tumors (MRT). MRT is a rare pediatric cancer that commonly starts in the kidneys. Dr. Pavlos Msaouel, who was a 2017 Conquer Cancer Foundation Young Investigator Award recipient supported by the Kidney Cancer Association, was involved in this breakthrough finding.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news

Merck, Pfizer post positive results for kidney cancer combo
A combination of treatments from Merck and Pfizer has shown to extend the life of patients with advanced kidney cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 19, 2019 Category: Pharmaceuticals Source Type: news

Health Highlights: Feb. 18, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Immunotherapies Prove Their Mettle Against Kidney Cancer Adding immunotherapy to targeted cancer therapy boosted survival for kidney cancer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 19, 2019 Category: General Medicine Source Type: news

First molecular test that selects immunotherapy for kidney cancer
(SingHealth) National Cancer Centre Singapore and Lucence Diagnostics Announce First Molecular Test that Selects Immunotherapy for Kidney Cancer. - Study was conducted on 36 kidney cancer patients using the CLEARScore ™ test that identifies eight genes linked to immunotherapy. - Findings from this study will be presented at the 2019 ASCO Genitourinary Cancers Symposium in San Francisco. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2019 Category: Cancer & Oncology Source Type: news

ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma
During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer
At ASCO GU in San Francisco, Dr. Samra Turajlic discussed the evolution of metastatic renal cell carcinoma.02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news

No Survival Bump Yet with Tivozanib for RCC
(MedPage Today) -- Selected studies on kidney cancer from the Genitourinary Cancers Symposium (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 18, 2019 Category: Primary Care Source Type: news

Merck, Pfizer drug combo extends kidney cancer survival: study
A combination of Merck& Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - February 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Immunotherapies could change kidney cancer care, studies suggest
The way doctors typically approach kidney cancer treatment could be evolving. (Source: CNN.com - Health)
Source: CNN.com - Health - February 16, 2019 Category: Consumer Health News Source Type: news

Drug combination may become new standard treatment for advanced kidney cancer
(Dana-Farber Cancer Institute) A combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 16, 2019 Category: International Medicine & Public Health Source Type: news

Recurring infections could lead to delayed bladder or kidney cancer diagnosis
(Cancer Research UK) Women with bladder or kidney cancer may lose out on a prompt diagnosis if they are already being regularly treated for recurring urinary tract infections (UTIs), according to new research presented at Cancer Research UK's Early Diagnosis Conference in Birmingham today (Wednesday). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2019 Category: Cancer & Oncology Source Type: news

Pembrolizumab Plus Axitinib vs Standard Treatment For mRCC
Treatment with pembrolizumab plus axitinib improved response and survival compared with sunitinib in patients with advanced, or metastatic clear-cell renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU
Merck announced yesterday that new combination and monotherapy data from the company ’s broad immuno-oncology research program in genitourinary cancers – renal, prostate and bladder − will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16.02/12/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 12, 2019 Category: Urology & Nephrology Source Type: news

Aerobics, Strength Exercises Improve Quality of Life in Kidney Cancer Survivors
Meeting combined exercise guidelines – including both aerobics and strength training – improved quality of life in #KidneyCancer survivors; however, few individuals reported they follow such guidelines, according to study findings published in Psycho-Oncology.02/12/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 12, 2019 Category: Urology & Nephrology Source Type: news

New Standard of Care for Metastatic Renal Cell Carcinoma New Standard of Care for Metastatic Renal Cell Carcinoma
Combination treatment with pembrolizumab and axitinib significantly improved survival outcomes as compared with sunitinib.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Merck, Pfizer combo treatment boosts kidney cancer survival
Drugmaker Merck& Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent. (Source: Reuters: Health)
Source: Reuters: Health - February 12, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Merck’s Keytruda trial a boost for kidney cancer patients
The immunotherapy used with Pfizer’s Inlyta halves the risk of dying from condition (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 11, 2019 Category: Pharmaceuticals Source Type: news

Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer
Nephron-sparing surgery (NSS) remains gold standard for the treatment of localised renal cell cancer (RCC), even in the case of a normal contralateral kidney.02/08/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 8, 2019 Category: Urology & Nephrology Source Type: news

Healthy woman dies after doctors wrongly removed BOTH kidneys after misdiagnosing her with cancer
Linda  Woolley, 73, of Englewood, Colorado, was on the transplant list when she suffered a fatal cardiac arrest on Friday, her family said. She was misdiagnosed with 'likely' kidney cancer in March. (Source: the Mail online | Health)
Source: the Mail online | Health - February 6, 2019 Category: Consumer Health News Source Type: news

Healthy woman dies after doctors wrongly removed BOTH kidneys after misdiagnosing her with cancer
Linda Woolley, 73, of Englewood, Colorado, was on the transplant list when she suffered a fatal cardiac arrest on Friday, her family said. She was misdiagnosed with 'likely' kidney cancer in March. (Source: the Mail online | Health)
Source: the Mail online | Health - February 6, 2019 Category: Consumer Health News Source Type: news

Comparative study of renal cell carcinoma in patients less than 40 years of age and older age patients: A retrospective single-center study
Renal cell carcinoma (RCC) is typically found in the older age group between 50 and 70 years of age. However, diagnosis of renal cancer is increasing more rapidly in patients less than 40 years if age compared to older age patients.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study
Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news

If Someone in Your Life Just Survived Cancer, Here ’s How You Can Support Them Now
This article explains how to support a loved one after cancer treatment.02/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 5, 2019 Category: Urology & Nephrology Source Type: news

Newsmakers: Promotions and appointments of area executives
Gretchen Vaughan, Kidney Cancer Association, has been named chief executive officer of the nonprofit.02/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 4, 2019 Category: Urology & Nephrology Source Type: news